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Abstract The chemokine receptor CCR5 belongs to the
class of G protein-coupled receptors. Besides its role in
leukocyte trafficking, it is also the major HIV-1 coreceptor
and hence a target for HIV-1 entry inhibitors. Here, we
report Escherichia coli expression and a broad range of
biophysical studies on E. coli-produced CCR5. After sys-
tematic screening and optimization, we obtained 10 mg of
purified, detergent-solubilized, folded CCR5 from 1L cul-
ture in a triply isotope-labeled (2H/15N/13C) minimal
medium. Thus the material is suitable for NMR spectro-
scopic studies. The expected a-helical secondary structure
content is confirmed by circular dichroism spectroscopy.
The solubilized CCR5 is monodisperse and homogeneous
as judged by transmission electron microscopy. Interac-
tions of CCR5 with its ligands, RANTES and MIP-1b were
assessed by surface plasmon resonance yielding KD values
in the nanomolar range. Using size exclusion chromatog-
raphy, stable monomeric CCR5 could be isolated. We
show that cysteine residues affect both the yield and oli-
gomer distribution of CCR5. HSQC spectra suggest that
the transmembrane domains of CCR5 are in equilibrium
between several conformations. In addition we present a
model of CCR5 based on the crystal structure of CXCR4 as
a starting point for protein engineering.
Keywords CCR5  G protein-coupled receptor 
Expression in E. coli  NMR  Homology modeling
Introduction
G protein-coupled receptors constitute a large protein
superfamily found only in eukaryotes. About 4 % of the
protein-coding human genome codes for *800 GPCRs
(Takeda et al. 2002). Based on phylogenetic analysis
human GPCRs cluster into 5 main families: rhodopsin,
adhesion, frizzled/taste2, glutamate and secretin, which
comprise 701, 24, 24, 15 and 15 members, respectively
(Fredriksson et al. 2003). The diversity of the GPCR
superfamily members is reflected in the variety of their
ligand types. Photons, ions, odorants, nucleotides, fatty
acids, amino acids, peptides and proteins are only some of
the messages that GPCRs can transduce (Overington et al.
2006). As GPCRs regulate so many physiological pro-
cesses such as vision, smell, behavior, mood, immune
system, blood pressure, heart rate, digestion or homeosta-
sis, they remain the most commonly drugged protein
family (Bockaert and Pin 1999). About 40 % of prescribed
pharmaceuticals target GPCRs (Filmore 2004).
The structure determination of membrane proteins is
notoriously difficult due to the many obstacles impeding
membrane protein sample preparation and subsequent
structure determination. When this publication was written,
the Protein Data Bank (Bernstein et al. 1977) contained
about 86,000 entries, but only 364 unique membrane pro-
tein 3D structures (http://blanco.biomol.uci.edu/Membrane_
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Proteins_xtal.html) (White 2004). Solved GPCR struc-
tures are even sparser. Until now 16 unique GPCR
structures have been solved by X-ray crystallography: the
first being bovine rhodopsin (Palczewski et al. 2000)
followed by b2-adrenergic (Rasmussen et al. 2007;
Cherezov et al. 2007), b1-adrenergic (Warne et al. 2008),
adenosine A2A (Jaakola et al. 2008; Lebon et al. 2011),
dopamine D3 (Chien et al. 2010), CXCR4 (Wu et al.
2010) and several others. To obtain high-resolution
structural data the replacement of the intracellular (IC)
loop three with T4 lysozyme (Rasmussen et al. 2007),
thermostabilization (Warne et al. 2008) or stabilization by
anti- or nanobodies (Rasmussen et al. 2007) proved to be
successful strategies. Additionally, all crystallized GPCRs
were bound to an agonist (Lebon et al. 2011), an inverse
agonist (Cherezov et al. 2007; Kruse et al. 2012; Ras-
mussen et al. 2007) or most often to an antagonist (Chien
et al. 2010; Haga et al. 2012; Hanson et al. 2012; Jaakola
et al. 2008; Manglik et al. 2012; Shimamura et al. 2011;
Warne et al. 2008; Wu et al. 2010, 2012; Granier et al.
2012). Although not GPCRs, prokaryotic sensory rho-
dopsin II (Gautier et al. 2008) and proteorhodopsin
(Reckel et al. 2011) are examples of 7-TM domain pro-
teins solved by solution NMR spectroscopy. Very recently
the structure of E coli-expressed and refolded CXCR1 has
been determined in phospholipid bilayers using solid state
NMR spectroscopy (Park et al. 2012).
CCR5 (CC chemokine receptor 5) belongs to the c-
group of the rhodopsin family of GPCRs. It is found in the
plasma membrane of Th1 lymphocytes, macrophages, NK
cells and immature dentritic cells and is involved in various
infectious and inflammatory diseases as well as cancer
(Balistreri et al. 2007). Since humans carrying the D32
allele of the CCR5 gene, a 32-base pair deletion resulting
in a premature stop codon in the extracellular (EC) loop 2
and a nonfunctional receptor, are healthy, the exact role of
CCR5 is not completely understood.
The main interest in CCR5 is, however, a consequence
of its involvement in AIDS. R5-tropic HIV-1 infection
necessitates the sequential interaction of viral envelope
glycoprotein gp120 with CD4 and CCR5 (Choe et al.
1998). Two copies of the CCR5-D32 allele confer nearly
complete resistance to HIV-1 infection (Liu et al. 1996;
Samson et al. 1996). D32 occurs at 5–14 % frequency in
European Caucasians but not in African, Native American,
and East Asian populations (Stephens et al. 1998). This is
hypothesized to be a result of pandemics that took place in
Europe in medieval ages (Duncan et al. 2005). Successful
strategies to block HIV-1 entry have been developed based
on small-molecule inhibitors of CCR5 (Kondru et al. 2008)
as well as derivatives of its natural chemokine ligand
RANTES (Gaertner et al. 2008; Lederman et al. 2004;
Lusso et al. 2011; Nardese et al. 2001).
High-resolution structural data would greatly improve
the understanding of CCR5 function and the nature of its
interaction with the chemokine ligands RANTES, MIP-1a,
and MIP-1b, as well as substantially enhance possibilities
for anti-HIV-1 drug discovery. So far it has been very
challenging to obtain sufficient amounts of this protein
suitable for structural studies. Large-scale CCR5 expres-
sion at the yield of 1 mg/L was reported in insect cells
(Nisius et al. 2008) where screening for mutants is time-
consuming and isotope labeling is very costly and has not
been achieved for deuterium.
Alternatively, 1–3 mg/L of CCR3 but only 0.1–0.3 mg/L
of CCR5 was obtained from E. coli after fusing the N-ter-
minus of the chemokine receptor to the C-terminus of thio-
redoxin (Ren et al. 2009). However, the described expression
system relied on the usage of rich TB medium and ligand
binding of the expressed chemokine receptors was not
shown. Nevertheless, there is a growing number of various
GPCRs functionally expressed in E. coli (Attrill et al. 2009;
Baneres et al. 2003; Dodevski and Pluckthun 2011; Furuk-
awa and Haga 2000; Krepkiy et al. 2006; Shibata et al. 2009;
Weiss and Grisshammer 2002), including the chemokine
receptor CXCR1, which was expressed as a GST-CXCR1
fusion construct in 15N/13C-labeled form at 5 mg/L and after
reconstitution to proteoliposomes could bind IL-8 and acti-
vate G protein (Park et al. 2012).
Petrovskaya et al. have compared direct expression of
17 diverse GPCRs in E. coli to hybrid expression with the
N-terminal fusion partners OmpF or Mistic (Petrovskaya
et al. 2010). Interestingly, almost all GPCRs expressed in
the presence of a fusion partner at [5 mg/L yield, but for
most the expression was severely reduced in its absence.
Thanks to a better access to isotope labeling bacterial or
yeast expression systems are preferred for NMR, however,
a significant progress has been recently made in isotope
labeling in mammalian cells, which, unlike bacteria or
yeast, provide possibilities to obtain human posttransla-
tional modifications (Sastry et al. 2011).
Here we report a CCR5 production platform that yields up
to 10 mg of purified protein per 1 L of bacterial culture.
CCR5 is solubilized from E. coli without the requirement of
refolding. As the expression conditions were optimized in
minimal medium, triple isotope (2H/13C/15N) labeling does
not compromise the yield. In order to boost the expression,
we fused the N-terminus of CCR5 to well expressing small
proteins or signal sequences. A C-terminal 10His-tag and
rigorous washing conditions yield over 90 % purity after a
single IMAC purification step. The fusion partner can be
readily and quantitatively cleaved off by thrombin and sep-
arated on a size exclusion column, where CCR5 monomers
and dimers migrate as separate symmetric peaks. Both
monomers and dimers are monodisperse and homogeneous
as judged from electron micrographs. The expected a-helical
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secondary structure content is confirmed by circular
dichroism (CD) spectroscopy. When solubilized in a DDM/
CHAPS/CHS/DOPC mixture CCR5 interacts with RAN-
TES, MIP-1b and 2D7 with nanomolar affinities. Recorded
1H-15N HSQC spectra suggest that the TM domains of CCR5
are in equilibrium between several conformations. We also
show that the number of cysteine residues has a severe
impact on both protein yield and oligomeric state. Following
Hernanz-Falcon et al. (2004) two point mutations I52V and
V150A were introduced to reduce the tendency of dimer
formation, but no such reduction was observed. Our system
establishes a high-yield platform for biophysical and struc-
tural studies on CCR5.
Materials and methods
Generation of expression constructs
Plasmids pET28F10 and pMT10H10 containing the CCR2b
sequence fused to OmpF and Mistic were a generous gift
from Prof. A. Arseniev (Russian Academy of Sciences,
Moscow, Russia). Plasmid pCA528 was kindly provided by
Prof. A. Spang (Biozentrum, Basel, Switzerland). pET vec-
tors were obtained from Novagen. The E. coli-optimized
CCR5 DNA sequence in the pQE-T7 vector was generated
by GeneArt. The CCR5 gene was cloned using standard
molecular biology techniques. Plasmid DNA was amplified
with the QIAprep Spin Miniprep Kit (Qiagen). Point muta-
tions were carried out using the QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent Technologies). DNA
sequences of the cloned constructs can be found in the sup-
porting information Text S1.
Protein expression
Freshly transformed Rosetta 2 (DE3) Competent Cells
(Novagen) were transferred to 1–2 L of M9 medium after
overnight growth on LB agar plates. The cultures were
shaken in 5 L baffled flasks at 100 rpm at 37 C until
OD600 = 2.6–2.8. The cultures were cooled down on ice
with occasional shaking until the temperature dropped to
20–25 C. CCR5 expression was induced with 1 mM IPTG
and the cultures were shaken at 100 rpm at 20 C. After
harvesting, cells were pelleted and stored at -70 C.
For expression in D2O transformed cells were grown on
LB agar plates prepared in 50 % D2O. 1–2 L cultures were
preceded by 100 mL precultures grown until OD600 = 1.
All compounds used in the preparation of M9 medium in
D2O (including trace elements, vitamins, antibiotics) were
prepared in 99.8 % D2O. Uniform
15N- and 13C-labeling
was carried out using 15NH4Cl (98 %
15N, 1 g/L), and
[1H/13C6]-D-glucose (99 %
13C, 4 g/L) as the sole nitrogen
and carbon sources, respectively. Hence, the labeling effi-
ciency is expected as *98 % for 15N and *99 % for 13C.
Judging from strong peaks in the HN(CO)CA spectrum,
which showed no signs of 1JCH splitting in the absence of
1H decoupling during 13Ca evolution, the deuteration ef-
ficiciency is estimated as[80 %. This is in agreement with
the data of Otten et al. (2010) and is consistent with bac-
terial metabolism (Gottschalk 1986). Details of the M9
medium composition can be found in Text S2.
Expression of wild-type CCR5 in insect cells was per-
formed as described previously (Nisius et al. 2008).
Membrane fraction preparation
Frozen E. coli cell pellet (1 g) was suspended in 6–8 mL of
buffer A (20 mM HEPES pH 7, 150 mM NaCl, 10 % (v/v)
glycerol) supplemented with 0.5 mM PMSF, 5 mM ben-
zamidine and EDTA-free complete protease inhibitor
cocktail (Roche). Cells were broken using a French press at
31,600 psi. Cell debris was removed by centrifugation at
6,600g for 15 min. The supernatant was centrifuged at
126,000g for 15 min, and the resulting pellet (from now on
called membrane fraction) collected. After suspending in
buffer A, a 20 % (w/v) solution of the membrane fraction
was stored at -70 C.
The preparation of the insect cell membrane fraction
was carried out as described previously (Nisius et al. 2008).
Detergent screening
Frozen 20 % (w/v) solutions of the membrane fraction were
thawed, diluted twice and supplemented with detergent to
the final concentration of 2 %. Solubilization was carried out
at RT for 2 h with 1,000 rpm shaking. Unsolubilized mate-
rial was removed by centrifugation at 100,000g for 30 min.
The clarified supernatant (2 lL) was loaded onto a Protran
BA85 nitrocellulose membrane (Whatman) and dried at RT.
Dot blots were blocked, labeled with anti-His-tag antibody,
developed and quantified in the same way as western blots
described below. Detergents were obtained from Anatrace
with the exception of 1,2-diheptanoyl-sn-glycero-3-phos-
phocholine (DHPC, Avanti Polar Lipids).
Protein purification
A frozen 20 % (w/v) solution of membrane fraction was
thawed and supplemented to a final concentration of 0.5 M
NaCl, 20 mM KCl, 10 mM MgCl2 and 2.5 % FosCholine-
12 (FC-12). Protein solubilization was carried out at
4–8 C for 1–2 h. Unsolubilized material was removed by
centrifugation at 126,000g for 30 min. The clarified
supernatant was supplemented with 35 mM imidazole and
bound to Ni–NTA beads (Qiagen) for 2 h. The resin was
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washed with 100 column volumes of buffer B (20 m M
HEPES pH 7, 1 M NaCl, 60 mM imidazole, 10 % (v/v)
glycerol, 0.1 % FC-12). The protein was then eluted with
buffer C (20 mM HEPES pH 7, 150 mM NaCl, 0.4 M
imidazole, 0.15 % FC-12). Protein-rich fractions were
pooled and dialyzed against buffer D (20 mM Tris pH 8,
150 mM NaCl, 0.5 mM EDTA, 0.1 % FC-12). To cleave
the fusion partner, 2 U of thrombin per 1 mg of purified
protein was sufficient to complete the cleavage over 16 h at
RT. The protein was concentrated using a 30 kDa molec-
ular weight cut off (MWCO) concentrator and injected
onto Superdex 200 10/300 GL (analytical run) or Superdex
200 26/60 HiLoad (preparative run) columns equilibrated
in buffer E (20 Na2HPO4 pH 7.4, 180 mM NaCl, 0.1 %
FC-12).
Gel electrophoresis and western blotting
Protein samples for SDS-PAGE were mixed with 59 SDS
loading buffer (312.5 mM Tris–HCl pH 6.8, 50 % (v/v)
glycerol, 25 % b-mercaptoethanol, 10 % SDS, 0.0125 %
bromophenol blue), incubated at 30 C for 15 min and
centrifuged at 17,000g for 5 min prior to loading on a
4–20 % gradient precast gel (Pierce). The electrophoresis
was performed at 100 V constant voltage. Gels were
stained using 0.25 % solution of Coomassie Brilliant blue
R-250 (AppliChem) in 25 % isopropanol and 10 % acetic
acid and destained in 10 % acetic acid.
For western blotting onto PVDF membrane (Bio-Rad), a
Criterion Blotter (Bio-Rad) was used. The transfer was
performed at 0.5 A constant current for 1 h in the transfer
buffer (48 mM Tris–HCl pH 9.2, 39 mM glycine, 0.375 %
SDS, 20 % methanol). The membrane was blocked with
3 % BSA in TBST buffer (10 mM Tris–HCl pH 8,
150 mM NaCl, 0.5 % Tween-20). Subsequently the
membrane was incubated with mouse monoclonal HIS-1
anti-polyhistidine-peroxidase antibody (Sigma-Aldrich) at
1:6,000 dilution for 1 h. After washing 4 9 2 min with
TBST buffer, the blot was developed using chemilumi-
nescent HRP substrate (Roche). The signal was recorded
using a BioMax XAR Film (Kodak) or using a LAS-4000
luminescent image analyzer (Fujifilm). The signal intensi-
ties were quantified using ImageJ 1.43r (Abramoff et al.
2004).
Transmission electron microscopy
For transmission electron microscopy (TEM) analysis 5 lL
of 10 lg/mL protein solution was adsorbed on carbon-
coated copper 200 mesh grids rendered hydrophilic by
glow discharge in air during 20 s. The grids were washed
in five drops of double distilled water and negatively
stained with two drops of 2 % uranyl acetate. Electron
micrographs were recorded on a Philips CM10 instrument
equipped with a LaB6 filament operating at an accelerating
voltage of 80 kV. Images were recorded at nominal defo-
cus values of 0.5 lm on a Veleta CCD camera at a nominal
magnification of 130,0009, corresponding to a pixel size
of 3.7 A˚ at the sample level.
CD spectroscopy
Circular dichroism spectra were recorded on 3–13 lM
monomeric CCR5 fractions. Measurements were performed
on a Chirascan CD spectrometer (Applied Photophysics) at
20 C in 1 mm quartz Suprasil cuvettes (Hellma). Typically,
spectra in a wavelength range of 195–260 nm spectra were
recorded in triplicates and averaged. After baseline (buffer)
subtraction, the mean residue molar ellipticity HMRM was
calculated from the following equation HMRM = H/
(C 9 n 9 l), where H is the ellipticity (deg), C is the con-
centration (mol/L), n is the number of residues and l is the
optical path length (cm). The relative a-helical content ar
was calculated as follows ar = (-HMRM,222 nm ? 3,000)/
39,000 (Morrow et al. 2000), where HMRM is given in units of
deg 9 cm2 9 dmol-1.
Surface plasmon resonance
Surface Plasmon resonance (SPR) interaction assays were
performed using a T100 Biacore instrument (GE Health-
care) at 20 C. The setup consisted of a CM5 chip on
which an antibody against the His-tag (Qiagen) was
immobilized, using amine coupling chemistry. The anti-
body (4,000–10,000 RU) could capture *2,000–5,000 RU
of recombinant His-tagged CCR5, solubilized from mem-
branes using a detergent mixture of 1 % DDM, 1 %
CHAPS, 0.2 % CHS, and 1 mM DOPC at pH 7. Thiore-
doxin removal was performed on the chip using 5 U of
thrombin injected in 300 lL over 60 min (5 lL/min).
Experiments were performed in buffer F (20 mM HEPES
pH 7.0, 150 mM NaCl, 0.1 % DDM, 0.1 % CHAPS,
0.02 % CHS, 50 nM DOPC, 0.1 mg/mL BSA) with a flow
rate of 50 lL/min. Signals were processed with the Biacore
T100 Evaluation Software using double referencing with
both a reference channel and blank injections.
NMR
Several samples of FC-12-solubilized m11CCR5 (mono-
meric fraction) produced in isotope labeled M9 medium
were concentrated in a 30 kDa MWCO Ultracel-30 K
Amicon Ultra Centrifugal Filter (Millipore) to 100–200 lM
(*2–3 % FC-12) and supplemented with 5 % D2O. All
spectra were recorded in Shigemi tubes on a Bruker
DRX800 spectrometer equipped with a triple resonance
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Z-gradient TCI cryoprobe. 1H-15N TROSY (Pervushin
et al. 1997) spectra were acquired under various buffer and
temperature conditions (see text) as data matrices of
63*(15N, t1) 9 512*(
1HN, t2) data points (where n* refers
to the number of complex points) with acquisition times of
25 ms (15N) and 40 ms (1HN). Standard three-dimensional
triple resonance TROSY spectra for backbone assignment
(Salzmann et al. 1999) were recorded on a sample of
200 lM uniformly 2H/13C/15N-labeled CCR5 in *3 %
FC-12 Foscholine at 20 C. Experimental times were
HNCO: 5.5 days, HNCA: 2.7 days, HN(CO)CA: 2.7 days,
HN(CA)CO: 6.4 days, and HNCACB: 7.3 days. All spec-
tra were processed using NMRPipe (Delaglio et al. 1995).
CCR5 model building
The core of CCR5 (residues 19–298) was built using the
SWISS-MODEL server (http://swissmodel.expasy.org/work
space) with the crystal structure of CXCR4 (3ODU (Wu et al.
2010), 32 % sequence identity) as a template. At the C-ter-
minus of CCR5, helix H8 modeled based on the rhodopsin
structure 3C9L (Stenkamp 2008) was added using VMD 1.9
(Humphrey et al. 1996). In addition, the N-terminus of CCR5
(residues 1–18) and another part of the C-terminus including
palmitoylated cysteines (residues 312–331) were added as an
extended amino acid chain. Residues 332–352 were not
included to reduce computational time. Finally, sulfate groups
were added to Tyr10 and Tyr14 as well as palmitoyl groups to
Cys321, Cys323 and Cys324.
After each manipulation step the structure was energy-
minimized and relaxed by a short molecular dynamic
simulation (MD) run using NAMD 2.7 (Phillips et al.
2005). For these MD runs the protein was embedded in a
lipid bilayer of 137 POPC molecules, hydrated with 10,774
TIP3 water molecules and neutralized by adding Na? and
Cl- ions. The final structure was embedded in a bilayer of
188 POPC molecules, hydrated with 20,781 TIP3 water
molecules, relaxed with several short (B1 ns) equilibration
steps and finally equilibrated with a 10 ns MD run.
Results
Protein expression
Even though many approaches are described in the litera-
ture, there is no universally applicable strategy to obtain a
high yield GPCR expression system. The selection of
expression vector, bacterial strain, culturing conditions,
etc. remains largely empirical. To increase the chance of
achieving high yield, we tested the expression of CCR5
cloned into several different T7-inducible vectors con-
taining various N- and C-terminal fusion partners/tags. The
summary of tested constructs can be found in Table 1. As
we intended to use the expression system also for isotope
labeling, expression was carried out in M9 minimal med-
ium supplemented with Hutner’s trace elements (Hutner
et al. 1950). To neutralize the codon bias in some of the
constructs we used Rosetta 2 (DE3) cells carrying the
pRARE plasmid encoding for rare tRNAs.
GPCR overexpression was assayed by western blot for
each of the cloned constructs. The expression in pET-22b
and pQE-T7 vectors, which provide no or only a very small
fusion partner, was clearly lower than in the others. This
suggests that CCR5 expression yield benefits from the
N-terminal fusion partner. However, the type of the fusion
partner seems of much less importance than expected
(Table 1). Therefore, shortly after the preliminary screen-
ing, the work was restricted to the TrxA-CCR5 fusion
construct, which was selected because of its high yield,
purity and convenience of separation, and since it can be
directly compared to the analogous expression system for
chemokine receptors developed by Ren et al. (2009).
For every tested fusion construct, the yield was signifi-
cantly higher at 20 C than at 37 C (Fig. 1a, b). A further
decrease of the temperature to 12 C or a decrease of IPTG
concentration from 1 mM to 0.1 mM resulted in a lower
yield (data not shown). The highest yield was achieved at
20 C at 24–48 h after induction (Fig. 1a–d).
For further optimization of the protein construct, it was
important to anticipate the sequence-specific position of the
secondary structure elements. Initially the constructs were
based on the two-dimensional topology predicted by Op-
permann (2004). However, after the crystal structure of
CXCR4 (Wu et al. 2010) became available, we generated a
homology model based on the latter structure and the
C-terminal helix H8 of rhodopsin (Stenkamp 2008) using
state-of-the-art molecular dynamics energy minimization
in explicit solvent of CCR5 embedded in a lipid bilayer.
The result of the simulation is shown as a full structural
model in Fig. 2 and the subsequently derived secondary
structure topology in Fig. 3a.
Anticipating problems with the formation of intermo-
lecular disulphide bridges we have systematically tested
the role of all 12 cysteines by the truncation of the cys-
teine-containing C-terminus (after N306 or R319) and site-
directed mutagenesis of the remaining 9 cysteines in other
regions. In these regions, solvent-exposed cysteines were
mutated to serines, whereas cysteines in the TM domains
were replaced by alanines. The locations of the respective
residues are highlighted in Figs. 2, 3a, and the naming
convention of the various mutants is listed in Fig. 3b.
The expression of these cloned constructs was moni-
tored by western blotting against the C-terminal His-tag.
The signal from the shorter (1–306) OmpF34-m2CCR5306
and Mistic-m2CCR5306 constructs was stronger than from
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Table 1 Summary of GPCR constructs tested for expression
Vector N-term. tag Fusion partner Cleavage site GPCRb cDNA C-term. tag Expression
pET28F10 – OmpF (1–34/362)a – CCR2b [1] H. sapiens 6His ???
pMT10H10 – Mistic (1–110/110) Thrombin CCR2b [5] H. sapiens 10His ???
pET-22b – pelB (1–22/374) pelB CCR5 [16] H. sapiens 8His ?
pGEV2 – GB1 (1–56/56) Thrombin CCR5 [15] H. sapiens 8His ???
pQE-T7 6His – TAGZyme CCR5 [14] E. coli – ?
pET28F10 – OmpF (1–34/362) – m7CCR5306 [4] E. coli 6His ???
pMT10H10 – Mistic (1–110/110) – m7CCR5306 [8] E. coli 10His ???
pET-41a – GST (1-218/218) – m7CCR5306 [18] E. coli 10His ???
pCA528 6His SUMO (1–98/101) Ulp1 m7CCR5306 [17] E. coli 10His ???
pET-32b – TrxA (1–109/109) Thrombin m7CCR5306 [11] E. coli 10His ???
a Residues 1–34 from 362 total
b The most frequently used constructs are listed in this Table. However, other ones (differing with regards to cleavage site, cDNA and C-terminal
tag) were also expressed. A comprehensive list of constructs with their DNA sequences is given in Text S1. The square brackets in Table 1 refer
to the numbers in Text S1
TrxA-CCR5
oligomers
CCR5 dimer
CCR5
TrxA-CCR5
dimer
TrxA-CCR5
TrxA
250
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75
50
37
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OmpF34-CCR2b OmpF34-CCR5306 OmpF34-CCR5319 Mistic-CCR2b Mistic-CCR5306 Mistic-CCR5319
TrxA-CCR5306 TrxA-m11CCR5306
m2 m9m7m6
TrxA-m11CCR5306
18   24 18   24 18   24 18   24
4    19 4   19 4    19 4   19 4   190    4    19 4    19 4    19 4   19 4    M   19 4   19 0     4    19[h] M M
20oC 20oC 20oC 20oC 20oC 20oC37oC 37oC 37oC 37oC 37oC 37oC[oC]
M
M M[h] 8  18   26  43
expression mem prep Ni-NTA
tot ins sol eluted 19    19inp FT FTinp
Ni-NTA dialysed cleaved
5     19
21 32 48 59 46 59
92 100
relative yield (%)
Fig. 1 Summary of the expression and purification of various CCR5
constructs in E. coli monitored by western blot and SDS-PAGE.
Comparison of the expression of longer (1–319) and shorter (1–306)
versions of OmpF34-m2CCR5 (a) and Mistic-m2CCR5 (b) constructs
at 20 C and 37 C. CCR2b constructs are used as a positive control.
c Comparison of the expression of various Cys mutants of TrxA-
CCR5306. d Expression, membrane preparation and binding to Ni–
NTA of TrxA-m11CCR5306. Broken E. coli cells expressing CCR5
were centrifuged to remove cell debris. The remaining suspension
(tot) was subsequently separated into insoluble membrane (ins) and
soluble cytoplasmic (sol) fractions. CCR5 was found in the membrane
fraction (ins) but not in the cytoplasmic fraction (sol). Solubilized
membranes (inp) were loaded on Ni–NTA. e Purification of
m11TrxA-CCR5306. After elution from Ni–NTA oligomerized
m11TrxA-CCR5306 was dialyzed and digested with thrombin
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the longer (1–319) OmpF34-m2CCR5319 and Mistic-
m2CCR5319 constructs (Fig. 1a, b). From this observation,
we concluded that the shorter constructs were either
expressing better or were more resistant to C-terminal
degradation. Therefore, further work was limited to the
shorter (1–306) CCR5 constructs (CCR5306). Within the
latter, a negative correlation exists between the expression
yield and the number of cysteine residues (Fig. 1c). Thus
TrxA-m2CCR5306 construct containing 7 cysteines
(Fig. 3b) expressed worse than TrxA-m7CCR5306 (4 Cys)
or TrxA-m6CCR5306 (3 Cys), and much worse than TrxA-
m9CCR5306 (0 Cys).
Detergent screening
A good detergent for membrane protein studies should be
able to solubilize the protein, keep it stable and functional
in solution as well as allow structural studies. In order to
explore the possible detergent space, we performed a sys-
tematic screen by solubilizing E. coli membrane fractions
in various detergents at 2 % (w/v) concentration. After
removal of the unsolubilized material, the clarified solu-
tions were dried on a nitrocellulose membrane and ana-
lyzed by dot blot using an anti-His antibody. The
chemiluminescent signal was quantified densitometrically
and normalized to the maximum value (Fig. 4a).
The results indicate that OmpF34-m7CCR5306 was effi-
ciently solubilized by anionic (sodium dodecanoyl sarcosine
and SDS) and zwitterionic detergents (FosCholines and
dimethyl glycines) with aliphatic chains. The cationic
trimethylammonium chlorides and the zwitterionic Anzer-
gents were intermediate to moderate in their solubilization
efficiency. Nonionic detergents (maltosides and Anapoes)
turned out to solubilize OmpF34-m7CCR5306 extremely
poorly with the single exception of tetradecylmaltoside,
which solubilized about a third as much as FosCholines.
These results on E. coli OmpF34-m7CCR5306 are similar
to a solubility screen carried out on wild-type CCR5
expressed in Sf21 cells (Fig. 4b). Analogous to E. coli
CCR5, the insect cell protein was efficiently solubilized by
sodium dodecanoyl sarcosine, SDS and FosCholines.
Dimethyl glycines, Anzergents and trimethylammonium
chlorides solubilized relatively worse and maltosides
somewhat better, but still not very efficiently.
Due to its relatively mild character and lipid-like
headgroup we picked FC-12 as the main working deter-
gent. Even though FosCholines with longer hydrocarbon
tails performed better, they are much less suitable for NMR
due to their high aggregation number and lower solubility.
Protein purification and identity confirmation
Considering a broad scope of applications we sought to
establish a simple, robust and efficient purification scheme.
Fractionation by centrifugation of the disrupted E. coli cells
showed that the expressed TrxA-m11CCR5306 was only
present in the membrane fraction and the heavier cell debris
fraction, but not in the soluble, cytosplasmic fraction
(Fig. 1d). The isolated membrane fraction was readily solu-
bilizable by a number of detergents (see Detergent screening
section). Similarly, the receptor could also be solubilized from
the cell debris. However, for most applications only the
preparation from the lighter fraction was used.
The solubilized TrxA-m11CCR5306 was purified in FC-
12 using Ni–NTA chromatography resulting in up to 10 mg
of *90 % pure (as estimated from SDS-PAGE) receptor
per 1 L of E. coli culture (Fig. 1d, e). Interestingly, puri-
fication by Ni–NTA triggered TrxA-m11CCR5306 oligo-
merization on SDS-PAGE, which was reversible by
dialysis (Fig. 1e). The fusion partner was cleavable with
thrombin (Fig. 1e). Other proteases were also tested (data
not shown) including TEV and 3C protease with no (TEV)
or partial success (3C).
Trials to solubilize the receptor in maltosides failed
(data not shown). Some TrxA-m11CCR5306 could be
purified in tetradecylmaltoside but precipitated within few
hours after elution from the Ni–NTA column. TrxA-
N
C
C224
C58
C20-C269
C101-C178
C213
C290
C291
C321
C323
C324
Y10
Y14
Fig. 2 Modeled 3D structure of CCR5 (residues 1–331) based on the
CXCR4 structure (Wu et al. 2010). Sulfation of Tyr10 and Tyr14 as
well as palmitoylated Cys321, Cys323 and Cys324 are depicted as
spheres
J Biomol NMR (2013) 55:79–95 85
123
m11CCR5306 solubilized in FC-12 followed by a detergent
exchange to dodecylmaltoside on Ni–NTA also resulted in
nearly complete protein precipitation.
The purified, cleaved m11CCR5306 migrated on SDS-
PAGE as a mixture of partially stable dimers at apparent
MW of *50 kDa and monomers at *30 kDa (Fig. 1e).
Both MW values are smaller than expected. This phe-
nomenon is common for membrane proteins and can be
caused by incomplete unfolding by SDS and/or by a larger
relative amount of SDS bound as compared to the soluble
protein standard. Besides monomers and dimers also higher
order oligomers were often observed (Fig. 1e), especially
after protein concentration.
Discrete and sharp bands of CCR5 monomer and oligo-
mers on the SDS-PAGE suggest that the primary structure of
the protein is maintained (Figs. 1e and S1). The identity and
integrity of the C-terminus of the expressed constructs were
confirmed by anti-His antibody western blotting (Fig. 1a–d).
To further confirm the protein identity, trypsinized TrxA-
m7CCR5306 and Mistic-m7CCR5306 were analyzed by mass
spectrometry. We were able to identify large stretches of
fusion partners and the N-terminal fragment of the receptor
in both monomer and oligomer (Fig. S1). Peptides from TM
domains were not detectable, which suggests that the CCR5
core was resistant to proteolysis.
Characterization of CCR5 size distribution, stability
and homogeneity
It is commonly observed that GPCRs form homo- and
heterodimers as well as higher oligomeric structures. For
both E. coli (Fig. 1) and insect cell expressed CCR5 (Ni-
sius et al. 2008), besides monomers also oligomers are
detected on SDS gels. The biological relevance of GPCR
Mutant Extracellular Cys Transmembrane Cys Intracellular Cys Other Mutations
C213A C290A C291A 
C58S C224S
C20S C101S C178S C269S
I52V V150A
m2CCR5306
m11CCR5306
m7CCR5306
m9CCR5306
m6CCR5306
C58S C224SC20S C101S C178S C269S C213A C290A C291A 
C20S C101S C178S C269S C213A C290A C291A C58S C224S I52V V150A
C58S C224S
C58S C224S
- - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - -
- - - - - - - - - -
- - - - - - - - - -
- - - - - - - - - -
a
b
Fig. 3 CCR5 topology and engineered mutations. a Membrane
topology prediction of the human CCR5 according to the CXCR4
homology model (Fig. 2). The grey rectangle approximates the
position of the membrane. EC (IC) space is at the top (bottom). The
potential posttranslational modifications include sulfation of Y3, Y10,
Y14 and Y15, phosphorylation of S336, S337, S342 and S349 (both
marked as black circles), palmitoylation of C321, C323 and C324 as
well as glycosylation of S4. The positions of mutated residues are
highlighted (C in blue, other in green). C-terminal truncations are
marked with red circles and potential helix H8 with dashed lines.
Disulphide bridges form between C20 and C269 and between C101
and C178. b Table summarizing the introduced point mutations of the
listed CCR5 mutants
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oligomerization is not clear. Since this heterogeneity also
presents a problem for structural studies, the question of
oligomerization was further investigated under non-reduc-
ing conditions using size exclusion chromatography.
After Ni–NTA purification and digestion by thrombin,
cleaved TrxA-m11CCR5306 was concentrated and injected
onto a Superdex 200 column. The receptor migrated as a
mixture of monomers, dimers and higher order oligomers
(Fig. 5a). This observation is consistent with the results of
the SDS-PAGE (Fig. 1e). Good protein separation was
achieved on a 60 cm long size exclusion column.
According to a column calibration with standard soluble
proteins, the monomer and dimer peaks migrated similarly
to particles of about 95 ± 3 (SD) kDa and 184 ± 9 kDa
MW, respectively (N = 7). This suggests that the mono-
meric (dimeric) protein micelle contains *165 (*313)
FC-12 molecules. The ratio of monomer and dimer
micelles depended on the stringency of Ni–NTA washing
conditions, since higher imidazole concentrations depleted
the monomeric fraction (data not shown). Apparently, this
is due to the weaker binding of monomers to Ni–NTA.
Relative to the monomers and dimers, the fraction of
higher order oligomers was much smaller.
In order to assay the influence of disulphide formation
on the quality of the preparation, several different cysteine-
containing CCR5306 mutants were compared to the cys-
teine-free mutant under non-reducing conditions by size
exclusion chromatography (Fig. 6). The number of cyste-
ines clearly correlates with enhanced oligomerization. The
m2CCR5306 mutant (7 Cys) formed the most oligomers,
whereas m6CCR5306 (3 Cys) and m7CCR5306 (4 Cys)
mutants were less oligomerized. Interestingly, the effect of
EC Cys mutations (m6CCR5306) seems similar to the effect
of TM Cys mutations (m7CCR5306), which suggests that
both EC and TM Cys may mediate disulphide bond for-
mation. The higher oligomer formation of the cysteine-
containing mutants could be suppressed by the addition of
a reducing agent (Fig. S2). Mutation of all Cys residues
(m9CCR5306 and m11CCR5306) resulted in a significant
reduction of oligomerization, essentially rendering most of
the protein monomeric or dimeric. Hence, it is likely that
the remaining dimers and the residual higher oligomers are
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Fig. 4 Detergent screening for solubilization of OmpF34-m7CCR5306
expressed in E. coli (a) and wild-type CCR5 expressed in Sf21 cells
(b). Values were normalized against FC-16. DHPC, DiMetPhOx-10,
n-decyl-N,N-dimethylamine-N-oxide; TriMetAmm-10, N-
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anoyl sarcosine; DiMetPhOx-8, dimethyloctylphosphine oxide;
HESO-8, N-octyl-2-hydroxyethyl sulfoxide; Maltoside-6, n-hexyl-b-
D-maltopyranoside
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stabilized by non-disulphide interactions, presumably
between the TM domains.
As non-dimerizing CCR5 would be of advantage for
structural studies, following the findings by Hernanz-Fal-
con et al. that point mutations I52V and V150A strongly
reduce dimer formation in HEK-293 cells (Hernanz-Falcon
et al. 2004), we tested these mutations in the m9CCR5306
mutant, which does not contain cysteines that could lead to
intermolecular disulphide bridges. In contrast to the in vivo
findings (Hernanz-Falcon et al. 2004), these mutations did
not reduce the dimerization propensity of the receptor
(Fig. 6).
To assess the stability of m7CCR5306 monomer and dimer
preparations under reducing conditions, both fractions were
concentrated to*40 lM and incubated for 5 days at RT. After
2 days of incubation, almost no change in the size distribution
was detected, whereas after 5 days only a small fraction of
monomers interconverted to dimers and some of dimers fell
apart to monomers or formed higher order oligomers (Fig. 5b).
We tested a maximum monomer m7CCR5306 concentration of
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Fig. 5 Monomers and dimers of m7CCR5306 and m11CCR5306.
a Size exclusion chromatography of m11CCR5306 on a Superdex 200
HiLoad 26/60 column. The 60 cm long column enables isolation of
monomers and dimers. b Stability test of m7CCR5306 monomers and
dimers. To prevent Cys oxidation 1 mM TCEP was included. Purified
monomers and dimers were concentrated separately to *40 lM and
re-run on a Superdex 200 10/300 GL column. For easier comparison
all six chromatograms were scaled to one. Negative stain pictures of
m7CCR5306 monomers (c) and dimers (d)
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137 lM, which also did not show any significant oligomeri-
zation after 4 days of incubation. Thus on the time scale of
several days, both monomer and dimer preparations are very
stable. The homogeneity of the monomeric and dimeric
m7CCR5306 was confirmed by negative stain TEM. Mono-
meric (Fig. 5c) and dimeric (Fig. 5d) particles had average
diameters of*6.6 and*8.3 nm, respectively.
Characterization of CCR5 secondary structure
The secondary structure content of several m7CCR5306
monomer preparations was assessed by CD. For all studied
constructs we observed double minima at about 208 and
222 nm characteristic for a-helical proteins (Fig. 7). The heli-
cal content derived from the mean residue molar ellipticity
HMRM,222 nm for Mistic-m7CCR5
306 (46 %) was slightly lar-
ger than for OmpF34-m7CCR5306 (43 %) and TrxA-
m7CCR5306 (42 %). This can be explained by the fact that
Mistic is a purely helical bundle and increases the HMRM of the
whole fusion construct. This is not the case for the other fusion
constructs, where the fusion partners contribute much less to
HMRM due to their mixed a/b (TrxA-m7CCR5
306) or likely b
secondary structure (OmpF34-m7CCR5306). The 42 % a-heli-
cal content of TrxA-m7CCR5306 is similar to the value of
*40 % obtained by Ren et al. for the thioredoxin-CCR3 fusion
construct (Ren et al. 2009). For the m7CCR5306 monomer, that
is after removal of the fusion partner from TrxA-m7CCR5306,
the CD signal was the strongest and indicated an a-helical
content of 52 %. This is in a good agreement with the*50 %
helical content of a typical GPCR (Baneres et al. 2003, 2005).
To assess the thermal stability of the CCR5 preparation,
the CD spectrum of TrxA-m7CCR5306 was followed over
the range from 5 to 95 C in 5 C increments (Fig. S3a).
With increasing temperature the spectrum lost amplitude
and its characteristic double minima. Decreasing the tem-
perature from 95 C back to 5 C did not restore the initial
shape and intensity, which indicates that denaturation was
irreversible. The plot of the ellipticity at 222 nm against
temperature (Fig. S3b) shows a very broad thermal tran-
sition between 20 and 80 C. Low thermal stability is
commonly observed for GPCRs. In the present case, this
problem may be aggravated by a non-optimal membrane-
mimicking detergent system, which lacks important lipids
and the rigidity of the two-dimensional membrane, as well
as the absence of stabilizing ligands.
Functional studies of CCR5
Due to the numerous differences in the expression
machinery and the cellular environment, the production of
functional GPCRs in heterologous systems is very chal-
lenging. To prove the proper folding and the functionality
of our CCR5 preparation, we tested binding of several
ligands to the receptor using SPR. High sensitivity, auto-
mation and high-throughput makes this method widely
used in the GPCR field for screening ligands (Navratilova
et al. 2011), solubilization (Navratilova et al. 2005) and
crystallization (Navratilova et al. 2006) conditions.
For the SPR experiments, the receptor was solubilized in
a DDM/CHAPS/CHS/DOPC mixture since a similar
detergent/lipid composition was demonstrated to give best
ligand binding activity for CCR5 and CXCR4 (Navratilova
et al. 2005) as opposed to FC-12 where little binding could
be detected. The protein was immobilized on the sensor
chip via an anti-His-tag antibody. Subsequently, TrxA was
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receptor without a fusion partner) normalized to the protein concen-
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7.4, 180 mM NaCl, 0.1 % FC-12 at 20 C on the monomeric receptor
fractions isolated on size exclusion chromatography. Each spectrum
shows characteristic features of a-helical secondary structure
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cut off from the N-terminus of the receptor by an injection
of thrombin. As monitored by the decrease of the SPR
signal, the cleavage efficiency was estimated to be typi-
cally about 70 % (Fig. S4).
Binding was assayed for the CCR5 chemokine ligands
RANTES and MIP-1b as well as for the conformation-
dependent antibody 2D7 (Fig. 8), which recognizes several
residues from the second EC loop (Khurana et al. 2005).
Each ligand showed fast binding and slow dissociation
reactions. KD values obtained from fitted kon and koff rates
were all in the nanomolar range. m7CCR5306 bound RAN-
TES with a KD of 1.6 nM. m11CCR5
306, in which cysteines
involved in disulphide bridge formation are absent, showed a
two-fold decreased affinity (KD = 3.1 nM) and a three-fold
decrease of the response amplitude. MIP-1b and 2D7 bound
with 71 nM and 2.8 nM affinity, respectively.
For comparison, an identical experiment was performed
with the wild-type CCR5 expressed in Sf21 cells. The
obtained KD values for RANTES, MIP-1b, 2D7 binding
are 2.6, 200, and 0.1 nM, respectively. A summary of the
performed experiments can be found in Table S1. Con-
sidering the differences in the protein constructs, the KD
values for E. coli and insect cell expressed CCR5 are in
reasonable agreement. However, when refractive index
amplitudes for ligand binding are normalized to the
refractive index amplitudes of bound CCR5 (Table S1), it
is evident that the amount of bound RANTES and MIP-1b
is about 2–3 fold and of 2D7 about 15 fold reduced for
E. coli m11CCR5306. We attribute this reduction to the lack
of closed disulphide bridges at the extracellular side and
the missing tyrosine sulfation in E. coli, which is important
for chemokine binding (Bannert et al. 2001).
NMR studies of CCR5
As opposed to crystal structures, which provide frozen
snapshots of GPCR structures, NMR in principle can give
simultaneous access to protein structure, dynamics and
interactions. Thus it emerges as a promising method to
rationalize GPCRs’ function. However, due to the numer-
ous challenges in the sample preparation, the success of
NMR studies on GPCRs has been very limited so far.
To make our system suitable for NMR, the expression
optimization was carried out directly in minimal medium.
In this way isotope labeling does not compromise the final
yield, which for detergent-solubilized, cleaved, monomeric
m11CCR5306 was 2 mg per 1L of cell culture in triply
isotope-labeled (2H/15N/13C) minimal medium. For NMR
measurements, samples were prepared from monomeric
CCR5 fractions of the m11CCR5306 mutant. To estimate
the quality of the preparation 1H-15N correlation spectra
were recorded (Figs. 9 and S5). To optimize spectral
quality, a variation of salt (0–180 mM NaCl), pH (4.2–7.4)
and temperature (5–35 C) was carried out. Optimal con-
ditions were found at 20 C, 0 mM NaCl and pH 4.2.
Under these conditions, the spectra did not change over a
period of few months. An increase in temperature to 35 C
gave only marginal improvement (data not shown). How-
ever, it had a destabilizing effect on the protein and caused
a decrease of the NMR signal over time. The spectrum of
m11CCR5306 under optimal conditions (Fig. 9a) has a
narrow dispersion, characteristic for an a-helical protein. It
contains on the order of 60–80 intense and narrow reso-
nances that presumably correspond to flexible backbone
amides in the N- and C-terminal tails and the interhelical
loops. Furthermore, a background of many more broad
resonances is observed that most likely correspond to
protein core residues. The line broadening in this region
may be related to intermediate conformational exchange
and/or to the large size of the protein/detergent micelle.
An attempt was made to assign at least some of the
better-resolved backbone resonances by three-dimensional
triple resonance TROSY HNCO, HN(CA)CO, HNCA,
HN(CO)CA, and HNCACB experiments (Salzmann et al.
1999). Due to the low signal to noise ratio, unambiguous
assignments could only be achieved for 21 residues within
the CCR5 amino acid sequence. These are located at the
N-terminus (M1-S7), in the loop between helix 6 and 7
(F264-S270), in helix 7 (L285-T288) as well as in the
putative helix 8 (V300-E302). The secondary 13Ca, 13C0
and 13Cb shifts for these residues are indicated in Fig. 9b. It
is obvious that most residues have close to random coil
shifts consistent with higher flexibility and concomitant
higher resonance intensity. However, residues L285-T288
show moderately positive (*1–2 ppm) and residues V300-
E302 larger positive (*2–3 ppm) 13Ca and 13C’ secondary
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shifts, which are consistent with a helical structure. Since
besides the flexible N-terminus only residues in the region
of helix 7 had a high enough signal to noise ratio for
assignment, one may speculate that the region of helix 7
displays increased flexibility or more generally a different
time scale of motional averaging. However, due to the
highly limited assignment, this statement should be con-
sidered as very preliminary.
Discussion
Due to its involvement in HIV-1 infection, CCR5 is a major
target for structural biology and the pharmaceutical industry.
Despite that expression and purification schemes have been
described for numerous GPCRs, there is a lack of an efficient
isotope labeling platform for CCR5. 1 mg/L expression of
CCR5 was reported in insect cells (Nisius et al. 2008) where
screening for mutants is time-consuming and isotope label-
ing very costly. On the other hand, so far no high-yield
expression in isotope-labeled form has been reported for
CCR5 in E. coli where these limitations are not present (Ren
et al. 2009). Our goal was to develop methods that allow
structural and biophysical characterization in particular by
NMR for CCR5 and potentially other GPCRs. Here, we have
achieved large overexpression of CCR5 by fusing small
stable protein domains or signal sequences to its N-terminus.
As the induction of CCR5 expression essentially arres-
ted E. coli growth, increasing cell density proved to be a
successful strategy to maximize the yield. The highest
receptor overexpression was observed 24–48 h post
induction at OD600 *3. The induction at earlier or later
phase of growth resulted in lower yields. Temperature had
a dramatic effect on the expression level with the optimum
*20 C. Variation of the CCR5 sequence also influenced
the final yield. Thus the expression of the longer CCR5
constructs (1–319) seemed much lower than the expression
of the shorter ones (1–306). The number of cysteines in the
CCR5 sequence correlated negatively with the expression
level. When all 9 Cys residues were mutated (TrxA-
m9CCR5306 and TrxA-m11CCR5306), the yield was high-
est, while it was lowest for TrxA-m2CCR5306 (2 IC Cys
mutated), i.e.*1/3 of TrxA-m11CCR5306.
A detergent screen revealed that charged detergents,
especially anionic and zwitterionic were very efficient in
OmpF34-m7CCR5306 solubilization. Nonionic detergents,
with the exception of tetradecylmaltoside, which solubi-
lized about *1/3 of available receptor, worked very
poorly. A very similar solubility pattern was observed for
the wild-type CCR5 receptor expressed in insect cells, i.e.
there is good solubility in charged detergents and low
solubility in nonionic detergents. In addition exchange
trials from FC-12 to maltoside consistently failed for
material from both expression systems. These observations
suggest that the poor CCR5 solubility in maltoside deter-
gents, which are widely used in GPCR research, is not
unique to the receptor expressed in E. coli and therefore
rather a consequence of the receptor’s low stability than a
problem specific to the bacterial expression. In this respect
it should be noted that the homology to other chemokine
receptors like CXCR4 and CXCR1, which have more
favorable solubilization properties, is not very high, i.e.
about 30 %. In particular, larger differences exist at the
CCR5 C-terminus, which harbors 3 cysteine palmitoylation
sites not present in CXCR1 and CXCR4.
The detergent screening results are in agreement with
previous screens proposing FosCholines as promising
candidates for CCR5 solubilization (Ren et al. 2009).
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Fig. 9 a 1H-15N TROSY
spectrum of 112 lM monomeric
2H/15N-labeled m11CCR5306
(5 mM sodium acetate pH 4.2,
5 % D2O, *3 % FC-12)
recorded at 20 C on an
800 MHz spectrometer
equipped with a cryoprobe with
a total experimental time of
18 h. Assigned resonances are
labeled. b Secondary 13Ca, 13C0
and 13Cb shifts for residues in
the CCR5 sequence, for which
backbone assignments could be
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Unfortunately, a good surfactant for solubilization is not
always also well suited for other purposes. For some
applications, like the SPR functional assay, other deter-
gents or detergent/lipid mixtures provide better receptor
activity (Navratilova et al. 2011). Thus the search for an
optimal detergent system or efficient detergent exchange
protocols is still ongoing in our laboratory.
Protein oligomerization can severely decrease homoge-
neity of a sample and in this way compromise the quality of
a sample for structural studies. In the case of CCR5
expressed in E. coli, the Cys residues, besides affecting the
yield, also mediate oligomerization. Using size exclusion
chromatography we have shown that the number of cys-
teines in CCR5306 constructs correlates with the amount of
oligomerized protein (Fig. 6). The fact that Cys-mediated
oligomerization was also observed in the case of
m7CCR5306, for which all but the EC Cys were mutated,
may suggest that in our system, at least to some extent, EC
disulphide bridges are not properly formed. On the other
hand, the oligomerization of m6CCR5306, for which all but
the TM cysteines C213, C290, C291 were mutated, implies
that also TM Cys residues are reactive. This observation is
consistent with the homology model (Fig. 2), where C213
and C291 are located on the surface of the CCR5 core and
accessible for intermolecular disulphide formation.
When not jeopardized by intermolecular disulphide
bridge formation, CCR5 forms a mixture of monomers,
dimers and higher order oligomers. Due to their high sta-
bility, dimers and oligomers are also visible on SDS-
PAGE. Both monomeric and dimeric species can be sep-
arated, concentrated and studied separately. The intercon-
version between monomers and dimers occurs after few
days and goes both possible directions. As judged by TEM,
both fractions are homogenous and monodisperse with a
clear difference in size. Based on the retention volume, the
size of monomers and dimers was estimated to be 95 ± 3
(SD) kDa and 184 ± 9 kDa, respectively (N = 7).
Based on computer modeling followed by the cross-
linking of CCR5-transfected cells it was proposed that two
point mutations together I52V and V150A yield a non-
signaling, non-dimerizing mutant of CCR5 (Hernanz-Fal-
con et al. 2004). Such a non-dimerizing CCR5 mutant
would be highly desirable for NMR studies. Unfortunately,
the I52V and V150A mutants (m7CCR5306 or
m11CCR5306) did not exhibit significantly smaller pro-
pensity for dimerization in comparison to the non-mutated
forms of CCR5 (Fig. 6). This is in line with results of co-
immunoprecipitation and BRET experiments (Lemay et al.
2005) that contradict the impairment of CCR5 dimerization
for these mutants. The involvement of these two residues in
dimerization is further challenged by the recently published
CXCR4 structure, which shows dimer interactions at
unrelated surfaces, i.e. by helices V and VI (CXCR4 bound
to IT1t) or by the intracellular ends of helices III and IV
(CXCR4 bound to CVX15) (Shimamura et al. 2011).
Due to its robustness, polyhistidine-tag chromatography
is widely used as a first purification step. Using a 10His-tag
we achieved strong binding and could apply more rigorous
washing conditions without compromising the final yield.
This resulted in *10 mg of purified TrxA-m11CCR5306
from 1 L of E. coli culture. This is a considerable
improvement over the previously described system, where
*0.3 mg of Trx-hCCR5 per L was reported (Ren et al.
2009). Importantly, this yield is not compromised when
isotope labeling including D2O is applied, which makes our
system fully suitable for NMR studies. Out of 10 mg of
TrxA-m11CCR5306 oligomeric mixture it is possible to
isolate 2 mg of cleaved monomeric m11CCR5306.
The quality of our preparations was assessed by CD,
where all m7CCR5306 constructs showed the characteristic
features of an a-helical secondary structure. NMR supports
this observation as the HSQC spectrum of m11CCR5306
exhibits, typical for a-helical proteins, rather narrow peak
dispersion (*2 ppm). Based on the circular dichroism
data, we estimate that a-helices constitute *52 % of the
sequence of m7CCR5306 monomer which suggests that the
receptor produced with our method has a correct secondary
structure. The CD data indicate that the thermal stability of
CCR5 is not very high. Some secondary structure is already
lost at 5 C but, as the amplitude of these changes is rel-
atively small, it is difficult to judge their consequence on
CCR5 structure and activity. Low thermal stability can be
explained by several factors, most importantly suboptimal
detergent system, lack of important lipids, absence of a
ligand, nano/antibody or a small molecule drugs, that
would stabilize CCR5.
The quality of the protein preparation was further vali-
dated by an SPR interaction assay. We observed nanomolar
binding of RANTES to m7CCR5306 (KD = 1.6 nM) and
m11CCR5306 (3.1 nM) and of MIP-1b to m11CCR5306
(70 nM). These affinities are comparable to affinities of
insect cell expressed CCR5 and within one order of mag-
nitude to values observed in cellular binding assays
(RANTES 0.38 nM, MIP-1b 7.2 nM) (Bannert et al. 2001).
The observed affinities may be affected by the lack of
posttranslational modifications (tyrosine sulfation) in
E. coli, which increase the affinity of CCR5 for chemo-
kines (Bannert et al. 2001). Furthermore, compared to
m7CCR5306 RANTES affinity is weaker for m11CCR5306,
which lacks the extracellular cysteines. This is consistent
with the reported importance of the extracellular disulphide
bridges for chemokine binding (Blanpain et al. 1999).
High-affinity (2.8 nM) binding of m11CCR5306 was also
observed for the 2D7 antibody, which is commonly used as
a native conformation probe. Nevertheless, this affinity is
considerably lower than for the insect cell CCR5 (0.1 nM).
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In addition, the refractive signal amplitudes (Table S1) also
suggest that the amount of bound ligand relative to
m11CCR5306 is about 2–3 times smaller for chemokines
and about 15 times smaller for 2D7. Again the lack of
tyrosine sulfation and extracellular disulphide bridges may
be the reason for this finding. Thus further efforts are
necessary to obtain higher activity, e.g. by proper refolding
of disulphide bridges under controlled conditions.
Due to the substantial challenges in the preparation of
isotope labeled samples, NMR spectra of GPCRs are very
sparse in the literature. Therefore, only few HSQC spectra
of 15N labeled GPCRs have been reported, including the
vasopressin V2 receptor (Tian et al. 2005), bovine rho-
dopsin (Werner et al. 2008), and the chemokine CXCR1
receptor (Park et al. 2011).
Here, we present a spectrum of uniformly 15N-labeled
m11CCR5306. Our initial HSQC spectrum had low disper-
sion and very broad lines besides for a number of apparently
mobile terminal or loop residues. Similar observations have
been made for other GPCRs (Park et al. 2011; Tian et al.
2005; Werner et al. 2008). However, the quality of the
m11CCR5306 spectrum could be improved by a decrease of
the pH from 7.4 to 4.2 and the removal of salt, which reduced
hydrogen exchange and increased the sensitivity of the
measurement. Unfortunately, even with these improvements
the quality of the spectra is still not sufficient for structural
analysis and needs further improvement but presents a
starting point in the NMR investigation of CCR5. Obviously,
the key bottleneck is the severe line broadening, which may
be the result of conformational heterogeneity of the TM
domains and/or chemical exchange on an intermediate time
scale in the microsecond to millisecond range. Therefore,
CCR5 stabilization by locking it in a single conformation,
may be an important step towards the improvement of the
NMR spectra.
Due to major difficulties in sample preparation for
structural studies, protein engineering is very common in
the GPCR field. This process alters the protein sequence
and may modify its native properties, but so far has been
indispensible for gaining insights into the structure and
function of this important class of proteins. Since a vast
majority of GPCR structures were solved by X-ray crys-
tallography, not surprisingly, alterations comprised stabil-
ization (rigidification, fixation in selected conformations),
removal of unstructured regions, introduction of a soluble
domain into a loop, etc.
NMR spectroscopy on the other hand requires isotope
labeling. However, so far efficient isotope labeling has not
been possible for insect cells or natural tissues from which
all except CXCR1 solved GPCRs were derived. Thus
simple prokaryotic organisms, like E. coli are often the
system of choice for an NMR spectroscopist, as they allow
cost-effective isotope labeling in addition to fast access to
protein engineering. Due to the size limitations of NMR,
the preparation of stable, monomeric and non-aggregating
GPCRs is vital. Taking advantage of E. coli, we developed
an efficient and robust CCR5 expression platform, which
may find applications in biophysical, functional as well as
structural characterizations of CCR5. We also believe that
many of our observations have more general character and
may be useful and applicable for other GPCRs.
Acknowledgments We thank Prof. A. Arseniev for providing the
plasmids pET28F10 and pMT10H10 and Prof. A. Spang for the
plasmid pCA528, Dr. Paul Jeno¨ and Suzanne Moes for mass spec-
trometry analysis as well as Dr. Marcel Blommers, Dr. Lukasz Skora
and Prof. Sebastian Hiller for stimulating discussions. This work was
supported by the EU FP7 Combined Highly Active Anti-Retroviral
Microbicides (CHAARM), SNF Grant 31-109,712 and SystemsX.ch
(C-CINA).
References
Abramoff MD, Magalhaes PJ, Ram SJ (2004) Image processing with
imageJ. Biophotonics Int 11:36–42
Attrill H, Harding PJ, Smith E, Ross S, Watts A (2009) Improved
yield of a ligand-binding GPCR expressed in E. coli for
structural studies. Protein Expr Purif 64:32–38
Balistreri CR, Caruso C, Grimaldi MP, Listi F, Vasto S, Orlando V,
Campagna AM, Lio D, Candore G (2007) CCR5 receptor:
biologic and genetic implications in age-related diseases. Ann
NY Acad Sci 1100:162–172
Baneres JL, Martin A, Hullot P, Girard JP, Rossi JC, Parello J (2003)
Structure-based analysis of GPCR function: conformational
adaptation of both agonist and receptor upon leukotriene B4
binding to recombinant BLT1. J Mol Biol 329:801–814
Baneres JL, Mesnier D, Martin A, Joubert L, Dumuis A, Bockaert J
(2005) Molecular characterization of a purified 5-HT4 receptor:
a structural basis for drug efficacy. J Biol Chem 280:
20253–20260
Bannert N, Craig S, Farzan M, Sogah D, Santo NV, Choe H, Sodroski
J (2001) Sialylated O-glycans and sulfated tyrosines in the NH2-
terminal domain of CC chemokine receptor 5 contribute to high
affinity binding of chemokines. J Exp Med 194:1661–1673
Bernstein FC, Koetzle TF, Williams GJ, Meyer EF Jr, Brice MD,
Rodgers JR, Kennard O, Shimanouchi T, Tasumi M (1977) The
protein data bank: a computer-based archival file for macromo-
lecular structures. J Mol Biol 112:535–542
Blanpain C, Lee B, Vakili J, Doranz BJ, Govaerts C, Migeotte I,
Sharron M, Dupriez V, Vassart G, Doms RW, Parmentier M
(1999) Extracellular cysteines of CCR5 are required for chemo-
kine binding, but dispensable for HIV-1 coreceptor activity.
J Biol Chem 274:18902–18908
Bockaert J, Pin JP (1999) Molecular tinkering of G protein-coupled
receptors: an evolutionary success. EMBO J 18:1723–1729
Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian
FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK,
Stevens RC (2007) High-resolution crystal structure of an
engineered human beta2-adrenergic G protein-coupled receptor.
Science 318:1258–1265
Chien EY, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, Shi L,
Newman AH, Javitch JA, Cherezov V, Stevens RC (2010)
Structure of the human dopamine D3 receptor in complex with a
D2/D3 selective antagonist. Science 330:1091–1095
J Biomol NMR (2013) 55:79–95 93
123
Choe H, Martin KA, Farzan M, Sodroski J, Gerard NP, Gerard C
(1998) Structural interactions between chemokine receptors,
gp120 Env and CD4. Semin Immunol 10:249–257
Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A (1995)
NMRPipe: a multidimensional spectral processing system based
on UNIX pipes. J Biomol NMR 6:277–293
Dodevski I, Pluckthun A (2011) Evolution of three human GPCRs for
higher expression and stability. J Mol Biol 408:599–615
Duncan SR, Scott S, Duncan CJ (2005) Reappraisal of the historical
selective pressures for the CCR5-Delta32 mutation. J Med Genet
42:205–208
Filmore D (2004) It’s a GPCR world. Mod Drug Discov 7:24–28
Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB (2003) The
G-protein-coupled receptors in the human genome form five
main families. Phylogenetic analysis, paralogon groups, and
fingerprints. Mol Pharmacol 63:1256–1272
Furukawa H, Haga T (2000) Expression of functional M2 muscarinic
acetylcholine receptor in Escherichia coli. J Biochem 127:
151–161
Gaertner H, Cerini F, Escola JM, Kuenzi G, Melotti A, Offord R,
Rossitto-Borlat I, Nedellec R, Salkowitz J, Gorochov G, Mosier
D, Hartley O (2008) Highly potent, fully recombinant anti-HIV
chemokines: reengineering a low-cost microbicide. Proc Natl
Acad Sci USA 105:17706–17711
Gautier A, Kirkpatrick JP, Nietlispach D (2008) Solution-state NMR
spectroscopy of a seven-helix transmembrane protein receptor:
backbone assignment, secondary structure, and dynamics. An-
gew Chem Int Ed Engl 47:7297–7300
Gottschalk G (1986) Bacterial Metabolism, 2nd edn. Springer, New
York
Granier S, Manglik A, Kruse AC, Kobilka TS, Thian FS, Weis WI,
Kobilka BK (2012) Structure of the delta-opioid receptor bound
to naltrindole. Nature 485:400–404
Haga K, Kruse AC, Asada H, Yurugi-Kobayashi T, Shiroishi M,
Zhang C, Weis WI, Okada T, Kobilka BK, Haga T, Kobayashi T
(2012) Structure of the human M2 muscarinic acetylcholine
receptor bound to an antagonist. Nature 482:547–551
Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, Reinhart G,
Desale H, Clemons B, Cahalan SM, Schuerer SC, Sanna MG,
Han GW, Kuhn P, Rosen H, Stevens RC (2012) Crystal structure
of a lipid G protein-coupled receptor. Science 335:851–855
Hernanz-Falcon P, Rodriguez-Frade JM, Serrano A, Juan D, del Sol
A, Soriano SF, Roncal F, Gomez L, Valencia A, Martinez AC,
Mellado M (2004) Identification of amino acid residues crucial
for chemokine receptor dimerization. Nat Immunol 5:216–223
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular
dynamics. J Mol Graph 14(33–8):27–28
Hutner SH, Provasoli L, Schatz A, Haskins CP (1950) Some
approaches to the study of the role of metals in the metabolism
of microorganisms. Proc Am Philos Soc 94:152–170
Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane
JR, Ijzerman AP, Stevens RC (2008) The 2.6 angstrom crystal
structure of a human A2A adenosine receptor bound to an
antagonist. Science 322:1211–1217
Khurana S, Kennedy M, King LR, Golding H (2005) Identification of
a linear peptide recognized by monoclonal antibody 2D7 capable
of generating CCR5-specific antibodies with human immunode-
ficiency virus-neutralizing activity. J Virol 79:6791–6800
Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S,
Dioszegi M (2008) Molecular interactions of CCR5 with major
classes of small-molecule anti-HIV CCR5 antagonists. Mol
Pharmacol 73:789–800
Krepkiy D, Wong K, Gawrisch K, Yeliseev A (2006) Bacterial
expression of functional, biotinylated peripheral cannabinoid
receptor CB2. Protein Expr Purif 49:60–70
Kruse AC, Hu J, Pan AC, Arlow DH, Rosenbaum DM, Rosemond E,
Green HF, Liu T, Chae PS, Dror RO, Shaw DE, Weis WI, Wess
J, Kobilka BK (2012) Structure and dynamics of the M3
muscarinic acetylcholine receptor. Nature 482:552–556
Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, Leslie
AG, Tate CG (2011) Agonist-bound adenosine A2A receptor
structures reveal common features of GPCR activation. Nature
474:521–525
Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M,
Piatak M Jr, Lifson JD, Salkowitz JR, Rodriguez B, Blauvelt A,
Hartley O (2004) Prevention of vaginal SHIV transmission in rhesus
macaques through inhibition of CCR5. Science 306:485–487
Lemay J, Marullo S, Jockers R, Alizon M, Brelot A (2005) On the
dimerization of CCR5. Nat Immunol 6: 535; author reply
535–536
Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R,
MacDonald ME, Stuhlmann H, Koup RA, Landau NR (1996)
Homozygous defect in HIV-1 coreceptor accounts for resistance
of some multiply-exposed individuals to HIV-1 infection. Cell
86:367–377
Lusso P, Vangelista L, Cimbro R, Secchi M, Sironi F, Longhi R,
Faiella M, Maglio O, Pavone V (2011) Molecular engineering of
RANTES peptide mimetics with potent anti-HIV-1 activity.
FASEB J 25:1230–1243
Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM,
Sunahara RK, Pardo L, Weis WI, Kobilka BK, Granier S (2012)
Crystal structure of the micro-opioid receptor bound to a
morphinan antagonist. Nature 485:321–326
Morrow JA, Segall ML, Lund-Katz S, Phillips MC, Knapp M, Rupp
B, Weisgraber KH (2000) Differences in stability among the
human apolipoprotein E isoforms determined by the amino-
terminal domain. Biochemistry 39:11657–11666
Nardese V, Longhi R, Polo S, Sironi F, Arcelloni C, Paroni R,
DeSantis C, Sarmientos P, Rizzi M, Bolognesi M, Pavone V,
Lusso P (2001) Structural determinants of CCR5 recognition and
HIV-1 blockade in RANTES. Nat Struct Biol 8:611–615
Navratilova I, Sodroski J, Myszka DG (2005) Solubilization,
stabilization, and purification of chemokine receptors using
biosensor technology. Anal Biochem 339:271–281
Navratilova I, Pancera M, Wyatt RT, Myszka DG (2006) A
biosensor-based approach toward purification and crystallization
of G protein-coupled receptors. Anal Biochem 353:278–283
Navratilova I, Besnard J, Hopkins AL (2011) Screening for GPCR
ligands using surface plasmon resonance. ACS Med Chem Lett
2:549–554
Nisius L, Rogowski M, Vangelista L, Grzesiek S (2008) Large-scale
expression and purification of the major HIV-1 coreceptor CCR5
and characterization of its interaction with RANTES. Protein
Expr Purif 61:155–162
Oppermann M (2004) Chemokine receptor CCR5: insights into
structure, function, and regulation. Cell Signal 16:1201–1210
Otten R, Chu B, Krewulak KD, Vogel HJ, Mulder FA (2010)
Comprehensive and cost-effective NMR spectroscopy of methyl
groups in large proteins. J Am Chem Soc 132:2952–2960
Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug
targets are there? Nat Rev Drug Discov 5:993–996
Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox
BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto
M, Miyano M (2000) Crystal structure of rhodopsin: a G protein-
coupled receptor. Science 289:739–745
Park SH, Casagrande F, Das BB, Albrecht L, Chu M, Opella SJ
(2011) Local and global dynamics of the G protein-coupled
receptor CXCR1. Biochemistry 50:2371–2380
Park SH, Das BB, Casagrande F, Tian Y, Nothnagel HJ, Chu M,
Kiefer H, Maier K, De Angelis AA, Marassi FM and Opella SJ
94 J Biomol NMR (2013) 55:79–95
123
(2012) Structure of the chemokine receptor CXCR1 in phospho-
lipid bilayers. Nature. doi:10.1038/nature11580.
Pervushin K, Riek R, Wider G, Wu¨thrich K (1997) Attenuated T2
relaxation by mutual cancellation of dipole–dipole coupling and
chemical shift anisotropy indicates an avenue to NMR structures
of very large biological macromolecules in solution. Proc Natl
Acad Sci USA 94:12366–12371
Petrovskaya LE, Shulga AA, Bocharova OV, Ermolyuk YS, Kryukova
EA, Chupin VV, Blommers MJ, Arseniev AS, Kirpichnikov MP
(2010) Expression of G-protein coupled receptors in Escherichia
coli for structural studies. Biochemistry (Mosc) 75:881–891
Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E,
Chipot C, Skeel RD, Kale L, Schulten K (2005) Scalable molecular
dynamics with NAMD. J Comput Chem 26:1781–1802
Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS,
Edwards PC, Burghammer M, Ratnala VR, Sanishvili R,
Fischetti RF, Schertler GF, Weis WI, Kobilka BK (2007)
Crystal structure of the human beta2 adrenergic G-protein-
coupled receptor. Nature 450:383–387
Reckel S, Gottstein D, Stehle J, Lohr F, Verhoefen MK, Takeda M,
Silvers R, Kainosho M, Glaubitz C, Wachtveitl J, Bernhard F,
Schwalbe H, Guntert P, Dotsch V (2011) Solution NMR
structure of proteorhodopsin. Angew Chem Int Ed Engl
50:11942–11946
Ren H, Yu D, Ge B, Cook B, Xu Z, Zhang S (2009) High-level
production, solubilization and purification of synthetic human
GPCR chemokine receptors CCR5, CCR3, CXCR4 and
CX3CR1. PLoS ONE 4:e4509
Salzmann M, Wider G, Pervushin K, Senn H, Wuthrich K (1999)
TROSY-type triple-resonance experiments for sequential NMR
assignments of large proteins. J Am Chem Soc 121:844–848
Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM,
Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyl-
dermans G, Verhofstede C, Burtonboy G, Georges M, Imai T,
Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G,
Parmentier M (1996) Resistance to HIV-1 infection in caucasian
individuals bearing mutant alleles of the CCR-5 chemokine
receptor gene. Nature 382:722–725
Sastry M, Xu L, Georgiev IS, Bewley CA, Nabel GJ, Kwong PD
(2011) Mammalian production of an isotopically enriched outer
domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy.
J Biomol NMR 50:197–207
Shibata Y, White JF, Serrano-Vega MJ, Magnani F, Aloia AL,
Grisshammer R, Tate CG (2009) Thermostabilization of the
neurotensin receptor NTS1. J Mol Biol 390:262–277
Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G,
Katritch V, Abagyan R, Cherezov V, Liu W, Han GW,
Kobayashi T, Stevens RC, Iwata S (2011) Structure of the
human histamine H1 receptor complex with doxepin. Nature
475:65–70
Stenkamp RE (2008) Alternative models for two crystal structures of
bovine rhodopsin. Acta Crystallogr D Biol Crystallogr D64:
902–904
Stephens JC, Reich DE, Goldstein DB, Shin HD, Smith MW,
Carrington M, Winkler C, Huttley GA, Allikmets R, Schriml L,
Gerrard B, Malasky M, Ramos MD, Morlot S, Tzetis M, Oddoux
C, di Giovine FS, Nasioulas G, Chandler D, Aseev M, Hanson
M, Kalaydjieva L, Glavac D, Gasparini P, Kanavakis E,
Claustres M, Kambouris M, Ostrer H, Duff G, Baranov V, Sibul
H, Metspalu A, Goldman D, Martin N, Duffy D, Schmidtke J,
Estivill X, O’Brien SJ, Dean M (1998) Dating the origin of the
CCR5-Delta32 AIDS-resistance allele by the coalescence of
haplotypes. Am J Hum Genet 62:1507–1515
Takeda S, Kadowaki S, Haga T, Takaesu H, Mitaku S (2002)
Identification of G protein-coupled receptor genes from the
human genome sequence. FEBS Lett 520:97–101
Tian C, Breyer RM, Kim HJ, Karra MD, Friedman DB, Karpay A,
Sanders CR (2005) Solution NMR spectroscopy of the human
vasopressin V2 receptor, a G protein-coupled receptor. J Am
Chem Soc 127:8010–8011
Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R,
Edwards PC, Henderson R, Leslie AG, Tate CG, Schertler GF
(2008) Structure of a beta1-adrenergic G-protein-coupled recep-
tor. Nature 454:486–491
Weiss HM, Grisshammer R (2002) Purification and characterization
of the human adenosine A(2a) receptor functionally expressed in
Escherichia coli. Eur J Biochem 269:82–92
Werner K, Richter C, Klein-Seetharaman J, Schwalbe H (2008)
Isotope labeling of mammalian GPCRs in HEK293 cells and
characterization of the C-terminus of bovine rhodopsin by high
resolution liquid NMR spectroscopy. J Biomol NMR 40:49–53
White SH (2004) The progress of membrane protein structure
determination. Protein Sci 13:1948–1949
Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R,
Brooun A, Wells P, Bi FC, Hamel DJ, Kuhn P, Handel TM,
Cherezov V, Stevens RC (2010) Structures of the CXCR4
chemokine GPCR with small-molecule and cyclic peptide
antagonists. Science 330:1066–1071
Wu H, Wacker D, Mileni M, Katritch V, Han GW, Vardy E, Liu W,
Thompson AA, Huang XP, Carroll FI, Mascarella SW, West-
kaemper RB, Mosier PD, Roth BL, Cherezov V, Stevens RC
(2012) Structure of the human kappa-opioid receptor in complex
with JDTic. Nature 485:327–332
J Biomol NMR (2013) 55:79–95 95
123
